🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Hyoscine Butylbromide During Transcystic Papillary Balloon Dilation for Choledocholithiasis

RecruitingNAAges 18 Years - anyAllRiga East Clinical University Hospital
NCT07814976 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of the PAPRELAX study is to evaluate the intraoperative effect of intravenous hyoscine butylbromide during laparoscopic transcystic balloon dilation of the papilla of Vater in adult patients undergoing surgical treatment for choledocholithiasis. The study will evaluate whether administration of hyoscine butylbromide influences the duration of transcystic papillary balloon dilation and the balloon inflation pressure required for papillary dilation. Eligible participants enrolled prospectively will receive 20 mg of intravenous hyoscine butylbromide during laparoscopic transcystic papillary balloon dilation. Procedural characteristics and postoperative outcomes will be compared with those of a historical control cohort of patients who previously underwent the same procedure without hyoscine butylbromide.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age 18 years or older. 2. Written informed consent for participation in the study. 3. Confirmed choledocholithiasis. 4. Common bile duct stone diameter of 15 mm or less. 5. General medical condition permitting laparoscopic cholecystectomy. Exclusion Criteria: 1. Age younger than 18 years. 2. Refusal to provide written informed consent. 3. Spontaneous antegrade evacuation of common bile duct stones during conservative treatment. 4. Previous cholecystectomy. 5. Common bile duct stone diameter greater than 15 mm. 6. General medical condition not permitting laparoscopic cholecystectomy.
💊

What it tests

  • Hyoscine Butylbromide
📍

Where

1 site
Riga East University Hospital
Riga, Latvia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy